<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070577</url>
  </required_header>
  <id_info>
    <org_study_id>030283</org_study_id>
    <secondary_id>03-AA-0283</secondary_id>
    <nct_id>NCT00070577</nct_id>
  </id_info>
  <brief_title>Influence of Age and Sex on Alcohol Metabolism and Acute Responses</brief_title>
  <official_title>Influence of Age and Sex on Alcohol Metabolism and Acute Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will examine age and sex differences in alcohol metabolism and the effects of
      alcohol. Men and women differ in their ability to metabolize alcohol, possibly due to
      differences between men and women in lean body mass, liver size, or the activity of enzymes
      that act on alcohol in the liver. Also, older men and women are thought to be more sensitive
      to alcohol, although the reasons for this are not clear.

      Healthy men and women between 21 and 25 years of age and between 55 and 65 years of age who
      are social drinkers may be eligible for this study. Candidates will be screened with
      questionnaires about their general and mental health, alcohol use, and family history of
      alcohol use and problems. They will have a physical examination, electrocardiogram (EKG),
      routine blood tests, urinalysis to test for drugs of abuse, and a blood test to study the
      gene responsible for enzymes that metabolize alcohol. Younger women will have a urine
      pregnancy test and older women will have a test to confirm post-menopausal status.

      Participants will have two study sessions at the NIH Clinical Center outpatient clinic. They
      come to the clinic by taxi and, upon arrival, take a breathalyzer test for any measurable
      alcohol levels. They are then given breakfast, after which two catheters (plastic tubes) are
      placed, one in a vein in each arm. One tube is used to collect blood samples for measuring
      hormone levels; the other is for infusing alcohol. The infusion is adjusted so that the
      breath alcohol level is held constant for about 3 hours at a moderate level. Baseline
      measurements are taken before the infusion begins. During and after the infusion, the
      participants fill out questionnaires about their moods and feelings. Breath alcohol level and
      heart rate measurements are monitored frequently. After the test, participants remain in the
      clinic until their breath alcohol level drops below 0.02 g/L (generally 2 to 3 hours after
      the infusion stops). They are given lunch and then sent home in a taxi.

      Participants also undergo a dual energy x-ray absorptiometry (DEXA) scan to determine lean
      body mass and a magnetic resonance imaging (MRI) scan of the abdomen to determine liver size.
      For the DEXA scan, the subject lies still on a table for about 30 minutes while the whole
      body is scanned using a small amount of radiation. For the MRI, the subject lies in a narrow
      metal cylinder (the scanner) about 30 minutes for the scan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies, including our studies using the alcohol clamp, have shown that alcohol
      pharmacokinetics differ between women and men. Some of the factors that may contribute to
      these sex differences in absorption, distribution and metabolism include variation in lean
      body mass (and total body water), liver size and differences in activity or capacity of
      alcohol metabolizing enzymes in the stomach and livers of women and men. A fundamental
      difference between men and women is in the levels of the sex hormones estrogen and
      testosterone, which can influence several of the above factors. Sex differences in alcohol
      pharmacokinetics, and estrogen itself, have been postulated as determinants of the increased
      susceptibility of women to alcohol-related liver disease. An additional area of interest is
      sex- and age-related differences in sensitivity to the effects of alcohol. The elderly are
      thought to be more sensitive to alcohol and show greater impairment than younger individuals.
      However, it is not clear if these changes are due to pharmacokinetic or pharmacodynamic
      factors.

      The objectives of this project are (I) to evaluate the influence of age and sex on alcohol
      elimination rates in men and women, and (II) to determine the influence of age and sex on the
      initial response and acute adaptation to alcohol on measures of subjective perceptions of
      alcohol effects and heart rate. This study will be conducted in 24 young and 24 older
      participants, with equal numbers of males and females in each group. Comparison of alcohol
      elimination rates across these groups and correlation with liver volume and sex steroid
      levels will provide a means to examine the influence of sex hormones, estrogen and
      testosterone, in age-related and sex-related differences in alcohol metabolism and liver
      volume. This study will examine age- and sex- related differences in response to alcohol on
      subjective measures of intoxication and mood, as well as on heart-rate and
      psychophysiological responses to emotional visual stimuli (pictures). This study will also
      evaluate the effect of acute alcohol administration on gene expression in peripheral blood
      cells. Findings from these studies will provide important new data regarding the role of sex
      steroids (estrogen and testosterone) on the metabolism of alcohol, and a better understanding
      of age- and sex-related differences in metabolic processes that may underlie medically
      important differences in the responses of individuals to alcohol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 29, 2003</start_date>
  <completion_date>May 3, 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Actual">65</enrollment>
  <condition>Metabolism</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        This study will be conducted in social drinkers with no current or past history of alcohol
        dependence or alcohol abuse. Inclusion criteria include:

          1. Male and female participants between 21-25 years or 55-65 years of age.

          2. Good health as determined by medical history, physical exam, EKG and lab tests.

          3. Current non-smokers. Participants who quit smoking for over 1 year can be included.

          4. Family-history negative, i.e., no family history of alcoholism in the first-or
             second-degree.

          5. Young women will have normal menstrual cycles and will be tested during the follicular
             phase of their cycle (within 7 days of offset of menses) and must have a negative
             urine pregnancy (hCG) test at the start of each study session.

          6. Older women will be post-menopausal, with cessation of menses for at least 12 months
             prior to enrollment into the study, and a serum follicle stimulating hormone (FSH)
             level greater than 40 IU/L.

          7. All participants must report the absence of flushing either currently or in the past,
             based on the Alcohol Flushing Questionnaire, assessed during screening.

          8. Participants must have no ferromagnetic objects in their bodies which might be
             adversely affected by MRI (e.g. surgical clips; metal fragments in any part of the
             body; cardiac or neurological pacemaker; cochlear or eye implant) - any doubt about
             presence of these objects will result in exclusion from this study.

        EXCLUSION CRITERIA:

          1. Current or prior history of any disease, including cardiovascular, respiratory,
             gastrointestinal, hepatic, renal, endocrine, or reproductive disorders, or a positive
             hepatitis or HIV test at screening.

          2. Current history of Axis-I psychiatric illness.

          3. Current or prior history of any alcohol or drug dependence or abuse, as well as
             non-drinkers (alcohol-naive individuals or current abstainers).

          4. Alcohol use exceeding 14 drinks/week for males and 7 drinks/week for females, and use
             of more than 4 drinks on any one occasion in the 6 months prior to the study.

          5. Positive result on urine drug screen.

          6. Pregnancy or intention to become pregnant for women. Female participants will undergo
             a urine beta-hCG test to ensure they are not pregnant.

          7. Use of oral contraceptive pills in younger female participants and use of hormone
             replacement therapy in older female participants.

          8. Menstrual cycle irregularities in younger female participants.

          9. Use of prescription or OTC medications known to interact with alcohol within 2 weeks
             of the study. These include, but may not be limited to: isosorbide, nitroglycerine,
             benzodiazepines, warfarin, cough-and-cold preparations which contain anti-histamines,
             codeine and/or acetaminophen, anti-depressants such as amitriptyline, clomipramine and
             nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide,
             H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, pain
             medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib
             and naproxen, anti-epileptics including phenytoin and phenobarbital and narcotics
             including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce enzymes
             that metabolize alcohol should not be used for 4 weeks prior to the study. These
             include acetaminophen, chlorzoxazone, isoniazid, metronidazole and disulfiram.

         10. Exclusions also include herbal preparations containing soy isoflavones (which may have
             estrogenic properties).

         11. Inability to undergo the MRI scan for liver volume due to claustrophobia or anxiety
             when confined to small spaces such as the magnet bore, or due to the presence of
             metallic implants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aasmoe L, Aarbakke J. Sex-dependent induction of alcohol dehydrogenase activity in rats. Biochem Pharmacol. 1999 May 1;57(9):1067-72.</citation>
    <PMID>10796077</PMID>
  </reference>
  <reference>
    <citation>Ammon E, Sch√§fer C, Hofmann U, Klotz U. Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther. 1996 May;59(5):503-13.</citation>
    <PMID>8646821</PMID>
  </reference>
  <reference>
    <citation>Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J. 1997 Jun;44(3):419-24.</citation>
    <PMID>9279518</PMID>
  </reference>
  <verification_date>May 3, 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 3, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2003</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Alcohol Clamp</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Alcohol</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Response</keyword>
  <keyword>Age</keyword>
  <keyword>Sex</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

